PepTalk 2017
PepTalk 2017

CONFERENCE SERIES: Biological Therapeutic Products

Recorded at: PepTalk: The Protein Science Week

Digital Course: Affecting Effector Functions to Optimize the Efficacy of Therapeutic Antibodies


Order DVD2011 SC6 DVD Cover About this Product:
Modifying antibodies’ effector functions offers a promising technology for creating more efficacious therapeutics.  The “Affecting Effector Functions” digital course provides both an excellent overview by Bill Strohl of how effector functions are currently being engineered by leading companies around the world, and also a case study from Chris Reyes illustrating how it’s done.  This course is designed for researchers who want to learn about engineering antibody therapeutics.


Agenda At A Glance: 

Mastering the ability to modify antibodies' effector functions -- whether a critically needed or unwanted component -- offers a promising approach to improving antibody properties. This course is focuses on characterizing and engineering effector functions in order to create more effective antibody therapeutics.

Tuning Fc Effector Functions for Optimal Antibody Design
William R. Strohl, Ph.D., VP, Biologics Research, Centocor R&D, Inc.
The engineering of therapeutic and clinical candidate monoclonal antibodies and Fc fusion proteins is becoming more sophisticated at generating molecules that are better suited to the pharmacological activity required of them.  There are at least 14 marketed and clinical candidate antibodies and Fc fusion proteins in which the Fc has been modified, either via changes in amino acid sequence or in glycoforms.  Recent research and development activities in Fc engineering to generate fit-for-purpose antibodies and Fc fusion proteins are reviewed.

Engineering Immune Effector-Less Antibodies: A Platform for Improved Scalability, Manufacturability, and Long-Term Stability
Christopher Reyes, Ph.D., Scientist II, Protein Chemistry, Biogen Idec
Antibodies elicit a number of potent cell killing mechanisms or effector functions mediated by the IgG Fc region of an antibody.  In certain therapeutic applications however, effector-function deficient antibodies should be selected to avoid potential toxicities due to the Fc mediated FcgR and C1q binding.  Until now, little effort has been applied to optimizing antibodies with reduced or non-existent effector function.  In the presentation, we demonstrate the utility of sequence-based protein design methods coupled with high-throughput protein screening to reduce FcgR and C1q binding and optimize the biophysical stability of effectorless aglycosylated antibodies.

  • Optimized biophysical properties by rational protein engineering 
  • Functional screening for no or low affinity for FcgRs and complement C1q 
  • Novel application of Fc engineering to process development challenges adversely impacting antibody drug development 

About this Product

2 Presentations
Over 60 Slides
84 Minutes
Individual Copy: $345
Site License: $1380

Speaker Biographies: 

William R. Strohl, Ph.D., VP, Biologics Research, Centocor R&D, Inc. 
William StrohlBefore becoming the Vice President of Biologics Research at Johnson & Johnson, Dr. Strohl was a Senior Director in Antibody Drug Discovery at Centocor.  Previously, he was an Executive Director at Merck.  Dr. Strohl received his doctorate in Microbiology and Biochemistry from Louisiana State University, and subsequently became a full Professor at Ohio State University.  His research interests include:  biologics, therapeutic monoclonal antibodies, antibody engineering (including, e.g., Fc engineering, humanization, affinity maturation technologies), phage-display technologies, follow-on biologics, natural products, microbiology, infectious diseases (primarily bacterial), antibacterial drugs, anti-tumor drugs, pharmaceutical drug discovery and the transition to preclinical development.

Christopher Reyes, Ph.D., Scientist II, Protein Chemistry, Biogen Idec
Christopher ReyesDr. Reyes co-founded and is the Chief Scientific Officer at Eclipse Therapeutics.  Prior to this position, he was a Scientist II in Molecular Discovery at Biogen Idec. Dr. Reyes received his doctorate in Biophysics from the University of California, San Francisco, and was a Postdoctoral Fellow at The Scripps Research Institute.  His research interests include: drug discovery and design, cancer stem cells, biophysics, protein/antibody engineering, biotechnology and of course, membrane protein crystallography.


About the Conference:
CHI’s 10th Annual PepTalk event features strong scientific programming comprising fourteen conferences within topic focused pipelines. The four distinct pipelines range from applying protein discovery research, to developing downstream protein expression, characterization, formulation, and production that ultimately leads to clinical applications. This event is designed with you in mind. Stay within a specific pipeline or track hop, and create a custom agenda to meet your research and networking needs.